# Evaluation of the Pharmacokinetics (PK) and Pharmacodymamics (PD) of Ganciclovir (GCV) in Premature Infants Receiving Treatment for Cytomegalorivus (CMV) Infection

> **NCT01602614** · — · COMPLETED · sponsor: **University of Alabama at Birmingham** · enrollment: 18 (actual)

## Conditions studied

- Cytomegalovirus Infections

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT01602614
- **Lead sponsor:** University of Alabama at Birmingham
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2013-04
- **Primary completion:** 2019-03
- **Final completion:** 2019-03
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2020-06-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01602614

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01602614, "Evaluation of the Pharmacokinetics (PK) and Pharmacodymamics (PD) of Ganciclovir (GCV) in Premature Infants Receiving Treatment for Cytomegalorivus (CMV) Infection". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01602614. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*